Shanghai, China - on August 28, 2019, the first implantation of the self-developed VitaFlow^® Transcatheter Aortic Valve System of MicroPort^® Cardioflow was performed at Zhongshan Hospital affiliated to Fudan University. Prof. Ge Junbo, Academician of Chinese Academy of Sciences, Director of the Cardiology Department of Zhongshan Hospital, performed the surgery and successfully implanted the VitaFlow^® aortic valve into a 70-year-old male patient.

In Shanghai, China on December 12, 2018, the self-developed VitaFlow^® II Transcatheter Aortic Valve and Recyclable Delivery System of MicroPort^® Cardioflow has been admitted into the “Green Path”from National Medical Products Administration (NMPA) for the special approval procedure for innovative medical devices. 

In Galway, Ireland on December 11, 2018, Shanghai MicroPort^® CardioFlow Medtech Co., Ltd. (hereinafter referred to as “MicroPort^® CardioFlow”) announced that the first patient enrollment was completed in Europe for the project of pre-market clinical research on its self-developed VitaFlow^® II Transcatheter Aortic Valve and Recyclable Delivery System (hereinafter referred to as “VitaFlow™ II System”) (“VITALE” project for short).